Relapses in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a retrospective study

被引:5
作者
Outh, Roderau [1 ]
Lemaire, Anne [1 ]
Mania, Alexandre [1 ]
Berland, Pauline [2 ]
Gerbaud, Laurent [2 ]
Aumaitre, Olivier [1 ]
Andre, Marc [1 ]
机构
[1] Ctr Hosp Univ, Serv Med Interne, Hop Gabriel Montpied, 58 Rue Montalembert, Clermont Ferrand 63003, France
[2] Ctr Hosp Univ, Serv Sante Publ, Hop Gabriel Montpied, Clermont Ferrand, France
关键词
Antineutrophil cytoplasmic antibodies; Vasculitis; Relapse; RHEUMATOLOGY; 1990; CRITERIA; WEGENERS-GRANULOMATOSIS; TREATMENT RESISTANCE; PREDICTORS; OUTCOMES; CLASSIFICATION; RITUXIMAB; RATES;
D O I
10.1007/s10067-019-04816-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To investigate the activity of relapsing events (RE) and their mode of presentation in patients with anti-neutrophil cytoplasmic (ANCA)-associated vasculitis (AAV). Methods Patients diagnosed with AAV between 1990 and 2015 experiencing at least one RE were investigated. The different organ involvements were registered during each RE. Presentation at initial onset (IO) and RE were compared. The Birmingham Vasculitis Activity Score was used to assess the activity. Results Ninety-nine patients were followed: 54 patients with 96 RE and 45 patients with none. The rate of RE was 53% with a median time of follow-up of 6.8 years. The mean time to first RE was 2.8 years. Thirty patients experienced one single RE, 15 had 2, 5 had 3, 2 had 4, and 2 had, respectively, 7 and 8. Fifty-five percent of RE had the same features as IO. Compared to IO, some clinical manifestations were less present: constitutional symptoms (29% vs 69%), ear-nose-throat (50% vs 76%), lung involvement (59% vs 76%), peripheral neuropathies (14% vs 24%), arthritis (7% vs 27%), kidney (25% vs 41%), and heart (4% vs 20%) (p < 0.001). Skin, eye, and bowel manifestations were not significantly less involved during RE. The mean Birmingham Vasculitis Activity Score at IO was 9.02 and 5.11 at relapse (p < 0.0001). Among the 96 RE, 46% had a new organ involvement compared to IO: none were life-threatening. Conclusion Global activity of RE in AAV patients is lower than that of IO. Fewer organs are involved in relapses. RE turned out to begin with the same manifestations as IO in most cases.center dot First study looking into clinical characteristics of relapses including mostly granulomatosis with polyangiitis.center dot Around half of patients with AAV seemed to relapse in a similar way compared to the initial diagnosis.center dot The activity score during relapsing events is less important.
引用
收藏
页码:1601 / 1608
页数:8
相关论文
共 33 条
  • [1] Boomsma MM, 2000, ARTHRITIS RHEUM-US, V43, P2025, DOI 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO
  • [2] 2-O
  • [3] Predictors of Treatment Resistance and Relapse in Chinese Patients with Antineutrophil Cytoplasmic Antibody-associated Disease
    Cao, Yali
    Tian, Zhigang
    Li, Wenge
    Ma, Li
    Yu, Yongchao
    Ren, Wenwen
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (05) : 916 - 922
  • [4] Chen M, 2008, J RHEUMATOL, V35, P448
  • [5] Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission
    Despujol, Carole Pierrot-Deseilligny
    Pouchot, Jacques
    Pagnoux, Christian
    Coste, Joel
    Guillevin, Loic
    [J]. RHEUMATOLOGY, 2010, 49 (11) : 2181 - 2190
  • [6] Long-term patient survival in ANCA-associated vasculitis
    Flossmann, Oliver
    Berden, Annelies
    de Groot, Kirsten
    Hagen, Chris
    Harper, Lorraine
    Heijl, Caroline
    Hoglund, Peter
    Jayne, David
    Luqmani, Raashid
    Mahr, Alfred
    Mukhtyar, Chetan
    Pusey, Charles
    Rasmussen, Niels
    Stegeman, Coen
    Walsh, Michael
    Westman, Kerstin
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (03) : 488 - 494
  • [7] Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3
    Fussner, Lynn A.
    Hummel, Amber M.
    Schroeder, Darrell R.
    Silva, Francisco
    Cartin-Ceba, Rodrigo
    Snyder, Melissa R.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    Langford, Carol A.
    Merkel, Peter A.
    Monach, Paul A.
    Seo, Philip
    Spiera, Robert F.
    St Clair, E. William
    Tchao, Nadia K.
    Stone, John H.
    Specks, Ulrich
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68 (07) : 1700 - 1710
  • [8] Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
    Guillevin, L.
    Pagnoux, C.
    Karras, A.
    Khouatra, C.
    Aumaitre, O.
    Cohen, P.
    Maurier, F.
    Decaux, O.
    Ninet, J.
    Gobert, P.
    Quemeneur, T.
    Blanchard-Delaunay, C.
    Godmer, P.
    Puechal, X.
    Carron, P. -L.
    Hatron, P. -Y.
    Limal, N.
    Hamidou, M.
    Ducret, M.
    Daugas, E.
    Papo, T.
    Bonnotte, B.
    Mahr, A.
    Ravaud, P.
    Mouthon, L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19) : 1771 - 1780
  • [9] EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis
    Hellmich, Bernhard
    Flossmann, Oliver
    Gross, Wolfgang L.
    Bacon, Paul
    Cohen-Tervaert, Jan Willem
    Guillevin, Loic
    Jayne, David
    Mahr, Alfred
    Merkel, Peter A.
    Raspe, Heiner
    Scott, David G. I.
    Witter, James
    Yazici, Hasan
    Luqmani, Raashid A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (05) : 605 - 617
  • [10] 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
    Jennette, J. C.
    Falk, R. J.
    Bacon, P. A.
    Basu, N.
    Cid, M. C.
    Ferrario, F.
    Flores-Suarez, L. F.
    Gross, W. L.
    Guillevin, L.
    Hagen, E. C.
    Hoffman, G. S.
    Jayne, D. R.
    Kallenberg, C. G. M.
    Lamprecht, P.
    Langford, C. A.
    Luqmani, R. A.
    Mahr, A. D.
    Matteson, E. L.
    Merkel, P. A.
    Ozen, S.
    Pusey, C. D.
    Rasmussen, N.
    Rees, A. J.
    Scott, D. G. I.
    Specks, U.
    Stone, J. H.
    Takahashi, K.
    Watts, R. A.
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 (01): : 1 - 11